- Home
- QIPT vs VIGL Comparison
QIPT vs VIGL Comparison
Compare QIPT & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- VIGL
- Stock Information
- Founded
- QIPT 1993
- VIGL 2020
- Country
- QIPT United States
- VIGL United States
- Employees
- QIPT N/A
- VIGL N/A
- Industry
- QIPT
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- VIGL Health Care
- Exchange
- QIPT Nasdaq
- VIGL Nasdaq
- Market Cap
- QIPT 118.5M
- VIGL 141.5M
- IPO Year
- QIPT N/A
- VIGL 2022
- Fundamental
- Price
- QIPT $2.36
- VIGL $3.00
- Analyst Decision
- QIPT Strong Buy
- VIGL Buy
- Analyst Count
- QIPT 3
- VIGL 5
- Target Price
- QIPT $7.67
- VIGL $16.80
- AVG Volume (30 Days)
- QIPT 143.2K
- VIGL 51.3K
- Earning Date
- QIPT 12-16-2024
- VIGL 11-07-2024
- Dividend Yield
- QIPT N/A
- VIGL N/A
- EPS Growth
- QIPT N/A
- VIGL N/A
- EPS
- QIPT N/A
- VIGL N/A
- Revenue
- QIPT $244,231,000.00
- VIGL N/A
- Revenue This Year
- QIPT $24.53
- VIGL N/A
- Revenue Next Year
- QIPT $3.69
- VIGL N/A
- P/E Ratio
- QIPT N/A
- VIGL N/A
- Revenue Growth
- QIPT 29.31
- VIGL N/A
- 52 Week Low
- QIPT $2.35
- VIGL $2.47
- 52 Week High
- QIPT $5.29
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- QIPT 29.15
- VIGL 32.87
- Support Level
- QIPT $2.35
- VIGL $2.89
- Resistance Level
- QIPT $2.77
- VIGL $3.26
- Average True Range (ATR)
- QIPT 0.10
- VIGL 0.22
- MACD
- QIPT -0.03
- VIGL -0.08
- Stochastic Oscillator
- QIPT 3.23
- VIGL 9.40
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.